mitoxantrone has been researched along with Cells, Neoplasm Circulating in 6 studies
Mitoxantrone: An anthracenedione-derived antineoplastic agent.
mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Furthermore, we evaluated the times for hematopoietic reconstitution in a group of five BC patients in the high-risk adjuvant situation who underwent HD chemotherapy and hematopoietic rescue with positive/negative selected stem cells and compared it with our own data from 10 BC patients who, after identical HD therapy, received only positively selected CD34+ cells and 14 patients who, after identical HD therapy, received autografts purged by incubation with toxic ether lipids (ET-18-OCH3)." | 2.69 | Efficacy and safety of simultaneous immunomagnetic CD34+ cell selection and breast cancer cell purging in peripheral blood progenitor cell samples used for hematopoietic rescue after high-dose therapy. ( Berdel, WE; Cassens, U; Fietz, T; Hilgenfeld, E; Hoffmann, M; Hoppe, B; Kienast, J; Knauf, WU; Koenigsmann, M; Mohr, M; Sibrowski, W; Thiel, E, 1999) |
| "With prostate cancer (PCa), circulating tumor cells (CTCs) and disseminated tumor cells (DTCs) portend a poor clinical prognosis." | 1.40 | Circulating tumor cells exhibit a biologically aggressive cancer phenotype accompanied by selective resistance to chemotherapy. ( Bergan, RC; Pavese, JM, 2014) |
| "For 13 (93%) of them, circulating tumor cells were detectable during the time of PSA response, i." | 1.32 | Quantification of disseminated tumor cells in the bloodstream of patients with hormone-refractory prostate carcinoma undergoing cytotoxic chemotherapy. ( Bilkenroth, U; Froehner, M; Fuessel, S; Kraemer, K; Linné, C; Meye, A; Schmidt, U; Wirth, MP, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pavese, JM | 1 |
| Bergan, RC | 1 |
| Atala, A | 1 |
| Schmidt, U | 1 |
| Bilkenroth, U | 1 |
| Linné, C | 1 |
| Fuessel, S | 1 |
| Kraemer, K | 1 |
| Froehner, M | 1 |
| Wirth, MP | 1 |
| Meye, A | 1 |
| Enoki, T | 1 |
| Kitada, K | 1 |
| Harada, E | 1 |
| Noshima, S | 1 |
| Hamano, K | 1 |
| Hirt, C | 1 |
| Schüler, F | 1 |
| Kiefer, T | 1 |
| Schwenke, C | 1 |
| Haas, A | 1 |
| Niederwieser, D | 1 |
| Neser, S | 1 |
| Assmann, M | 1 |
| Srock, S | 1 |
| Rohrberg, R | 1 |
| Dachselt, K | 1 |
| Leithäuser, M | 1 |
| Rabkin, CS | 1 |
| Herold, M | 1 |
| Dölken, G | 1 |
| Mohr, M | 1 |
| Hilgenfeld, E | 1 |
| Fietz, T | 1 |
| Hoppe, B | 1 |
| Koenigsmann, M | 1 |
| Hoffmann, M | 1 |
| Knauf, WU | 1 |
| Cassens, U | 1 |
| Sibrowski, W | 1 |
| Kienast, J | 1 |
| Thiel, E | 1 |
| Berdel, WE | 1 |
2 trials available for mitoxantrone and Cells, Neoplasm Circulating
| Article | Year |
|---|---|
Rapid and sustained clearance of circulating lymphoma cells after chemotherapy plus rituximab: clinical significance of quantitative t(14;18) PCR monitoring in advanced stage follicular lymphoma patients.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined | 2008 |
Efficacy and safety of simultaneous immunomagnetic CD34+ cell selection and breast cancer cell purging in peripheral blood progenitor cell samples used for hematopoietic rescue after high-dose therapy.
Topics: Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Combi | 1999 |
4 other studies available for mitoxantrone and Cells, Neoplasm Circulating
| Article | Year |
|---|---|
Circulating tumor cells exhibit a biologically aggressive cancer phenotype accompanied by selective resistance to chemotherapy.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Cell Line, Tumor; Cell Movement; Cell Survival; D | 2014 |
Re: Circulating tumor cells exhibit a biologically aggressive cancer phenotype accompanied by selective resistance to chemotherapy.
Topics: Animals; Antineoplastic Agents; Drug Resistance, Neoplasm; Humans; Male; Mitoxantrone; Neoplastic Ce | 2015 |
Quantification of disseminated tumor cells in the bloodstream of patients with hormone-refractory prostate carcinoma undergoing cytotoxic chemotherapy.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Estramustin | 2004 |
[A case of multiple lung metastases of hepatocellular carcinoma after resection of liver and tumor thrombi in the inferior vena cava responding to chemotherapy using 5-FU, mitoxantrone and CDDP].
Topics: alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cispl | 2007 |